First test of weekly shot aims to tackle diabetes and curb appetite
NCT ID NCT05363774
Summary
This was the first study in humans for a new medicine called NNC0519-0130. Researchers tested its safety and how the body processes it. They also looked for early signs it could help lower blood sugar and body weight in people with type 2 diabetes or who are overweight. The medicine was tested as both a weekly injection and a daily pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (DIABETES MELLITUS, TYPE 2) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novo Nordisk Investigational Site
Søborg, 2860, Denmark
-
Profil GmbH & Co. KG
Mainz, 55116, Germany
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.